ACE Pharmaceuticals has sold a majority stake to private investors and Quadrum Capital
October 2017 — The shareholders of ACE Pharmaceuticals have sold a majority stake in the company to private investors and Quadrum Capital, a Dutch private equity firm.
ACE Pharmaceuticals is a specialized company operating in the niche of medical need products which provide mainly small patient groups or specific indications. Through new, innovative products or by the revitalization of orphaned drugs, the company is able to ensure that these medical need products are or remain available. The company develops and distributes locally and abroad both licensed and non-licensed products. ACE Pharmaceuticals was founded more than 25 years ago as a producer of veterinary medicines. In the early 2000s, the company shifted its focus to human medical need products. Since then, it has experienced strong sales growth and has built an exciting product range and promising product pipeline.
Our role in the transaction
Oaklins's team in the Netherlands acted as M&A advisor to the shareholders of ACE Pharmaceuticals in this transaction.
Talk to the deal team
Sander van 't Spijker
Oaklins Netherlands
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Learn more